VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. In addition, the company develops CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of small molecule NCEs. VistaGen Therapeutics, Inc. has licensing, sublicensing, and collaboration agreements with BlueRock Therapeutics, LP; U.S. National Institutes of Health; Cato Research Ltd.; and University Health Network. The company was founded in 1998 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VTGN
CUSIPN/A
Phone650-577-3600
Debt
Debt-to-Equity RatioN/A
Current Ratio10.58
Quick Ratio10.58
Price-To-Earnings
Trailing P/E Ratio-0.85
Forward P/E Ratio-1.21
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.25 million
Price / Sales24.00
Cash FlowN/A
Price / CashN/A
Book Value$0.07 per share
Price / Book18.71
Profitability
EPS (Most Recent Fiscal Year)($1.54)
Net Income$-10,250,000.00
Net MarginsN/A
Return on Equity-590.91%
Return on Assets-220.63%
Miscellaneous
Employees9
Outstanding Shares22,900,000
Vistagen Therapeutics (NASDAQ:VTGN) Frequently Asked Questions
What is Vistagen Therapeutics' stock symbol?
Vistagen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN."
How were Vistagen Therapeutics' earnings last quarter?
Vistagen Therapeutics Inc (NASDAQ:VTGN) posted its quarterly earnings data on Thursday, November, 9th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.05. View Vistagen Therapeutics' Earnings History.
What price target have analysts set for VTGN?
3 brokers have issued 12-month target prices for Vistagen Therapeutics' shares. Their forecasts range from $6.00 to $22.00. On average, they anticipate Vistagen Therapeutics' share price to reach $11.3333 in the next year. View Analyst Ratings for Vistagen Therapeutics.
Who are some of Vistagen Therapeutics' key competitors?
Some companies that are related to Vistagen Therapeutics include Aptevo Therapeutics (APVO), Merrimack Pharmaceuticals (MACK), Leap Therapeutics (LPTX), Catalyst Biosciences (CBIO), Trevena (TRVN), TapImmune Inc. common stock (TPIV), Steadymed (STDY), Xenon Pharmaceuticals (XENE), Adamis Pharmaceuticals (ADMP), Northwest Biotherapeutics (NWBO), Sophiris Bio (SPHS), Aerpio Pharmaceuticals (ARPO), Proteostasis Therapeutics (PTI), Alpine Immune Sciences (ALPN) and Oramed Pharmaceuticals (ORMP).
Who are Vistagen Therapeutics' key executives?
Vistagen Therapeutics' management team includes the folowing people:
- Mr. Shawn K. Singh J.D., CEO & Director (Age 55)
- Dr. H. Ralph Snodgrass Ph.D., Founder, Pres, Chief Scientific Officer & Director (Age 68)
- Mr. Jerrold D. Dotson CPA, CFO, VP & Sec. (Age 65)
- Dr. Mark A. Smith M.D., Ph.D., Chief Medical Officer (Age 63)
- Mr. Mark Adrian McPartland, VP of Corp. Devel. (Age 52)
Has Vistagen Therapeutics been receiving favorable news coverage?
News stories about VTGN stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vistagen Therapeutics earned a daily sentiment score of 0.25 on Accern's scale. They also assigned media stories about the company an impact score of 46.22 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Vistagen Therapeutics' major shareholders?
Which institutional investors are selling Vistagen Therapeutics stock?
How do I buy shares of Vistagen Therapeutics?
Shares of VTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vistagen Therapeutics' stock price today?
One share of VTGN stock can currently be purchased for approximately $1.31.
How big of a company is Vistagen Therapeutics?
Vistagen Therapeutics has a market capitalization of $32.29 million and generates $1.25 million in revenue each year. The company earns $-10,250,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis. Vistagen Therapeutics employs 9 workers across the globe.
How can I contact Vistagen Therapeutics?
Vistagen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-577-3600 or via email at [email protected]
MarketBeat Community Rating for Vistagen Therapeutics (VTGN)
MarketBeat's community ratings are surveys of what our community members think about Vistagen Therapeutics and other stocks. Vote "Outperform" if you believe VTGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VTGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
